0070 Comparison of outcomes of transrectal ultrasound guided biopsy (TRUS) and transperineal template guided biopsy
Published Date: 01st September 2019
Publication Authors: Ejikeme C, Mistry R
Introduction
With the onset of PSA testing, more people are diagnosed with prostate cancer. TRUS guided biopsies has been used as a standard in all prostate re-biopsies. With MRI scans detecting possible prostate cancer foci and the advent of template, the role of TRUS biopsy is questioned for those on AS. The study determined if template re-biopsy resulted in more significant histology upgrade, better cancer specific and overall survivals TRUS.
Method(s)
231 patients on AS were identified from cancer registry, Data was collected form the Trust electronic system on inclusion criteria, follow up and outcomes.
Result(s)
155 patients had re-biopsy, 42 by TRUS, 99 by template and 14 had both. 19 (45%) out of 42 patients that had TRUS had histology upgrade. For template this was 34 (34%) and 6 (42%) out of 14 that had both biopsies had upgrade by template only. There is no statistical difference between both. TRUS and template re-biopsy modes resulted in 100% cancer-specific survival. The overall survival probability for TRUS vs template at 8 years is 0.87 vs 0.95, this is statistically significant.
Conclusion(s)
Outcomes of re-biopsy by TRUS compares favourably to that of template re-biopsy. Use ofMRI-ultrasound fusion biopsy will enhance the result of TRUS biopsy.
Ejikeme, C; Mistry, R. (2019). 0070 Comparison of outcomes of transrectal ultrasound guided biopsy (TRUS) and transperineal template guided biopsy of prostate in patient on active surveillance (AS) for low risk localised prostate cancer. British Journal of Surgery. 106 (S6), 153.